Accessibility Menu
 
ORIC Pharmaceuticals logo

ORIC Pharmaceuticals

(NASDAQ) ORIC

Current Price$10.22
Market Cap$1.03B
Since IPO (2020)-60%
5 Year-52%
1 Year+104%
1 Month-16%

ORIC Pharmaceuticals Financials at a Glance

Market Cap

$1.03B

Revenue (TTM)

$0.00

Net Income (TTM)

$129.47M

EPS (TTM)

$-1.51

P/E Ratio

-6.79

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$10.22

Volume

1,363,014.626

Open

$10.22

Previous Close

$10.23

Daily Range

$10.10 - $10.49

52-Week Range

$4.52 - $14.93

ORIC: Motley Fool Moneyball Superscore

54

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ORIC Pharmaceuticals

Industry

Biotechnology

Employees

104

CEO

Jacob M. Chacko, MD, MBA

Headquarters

South San Francisco, CA 94080, US

ORIC Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-41%

Return on Capital

-37%

Return on Assets

-32%

Earnings Yield

-14.73%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.03B

Shares Outstanding

100.36M

Volume

1.36M

Short Interest

0.00%

Avg. Volume

1.95M

Financials (TTM)

Gross Profit

$1.22M

Operating Income

$143.00M

EBITDA

$128.25M

Operating Cash Flow

$113.37M

Capital Expenditure

$712.00K

Free Cash Flow

$114.08M

Cash & ST Invst.

$281.49M

Total Debt

$11.55M

ORIC Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$320.00K

-5.3%

Gross Margin

0.00%

N/A

Market Cap

$1.03B

N/A

Market Cap/Employee

$8.46M

N/A

Employees

122

N/A

Net Income

$30.50M

+16.0%

EBITDA

$30.18M

+16.2%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$269.94M

+6.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$8.22M

N/A

Short Term Debt

$3.33M

+4.6%

Return on Assets

-31.50%

N/A

Return on Invested Capital

-36.61%

N/A

Free Cash Flow

$22.87M

+19.1%

Operating Cash Flow

$22.48M

+19.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PGENPrecigen, Inc.
$3.95+1.28%
INBXInhibrx Biosciences, Inc.
$83.11-0.58%
TRMLTourmaline Bio, Inc.
$47.98+0.00%
ATAIAtai Beckley N.V
$4.09+2.25%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.07-0.02%
QBTSD-Wave Quantum
$21.52+0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$56.43+0.01%
HIMSHims & Hers Health
$26.99+0.11%

Questions About ORIC

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.